Cinctive Capital Management LP Has $1.45 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Cinctive Capital Management LP lessened its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 36.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 36,035 shares of the company's stock after selling 20,766 shares during the quarter. Cinctive Capital Management LP owned approximately 0.06% of Kymera Therapeutics worth $1,450,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Blue Trust Inc. boosted its stake in Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after acquiring an additional 270 shares during the last quarter. KBC Group NV boosted its position in shares of Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after purchasing an additional 752 shares during the last quarter. Quarry LP acquired a new stake in shares of Kymera Therapeutics during the third quarter worth $95,000. KLP Kapitalforvaltning AS bought a new stake in Kymera Therapeutics in the fourth quarter valued at about $310,000. Finally, Thrivent Financial for Lutherans acquired a new position in Kymera Therapeutics in the third quarter valued at about $313,000.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Leerink Partners restated an "outperform" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Friday, December 27th. HC Wainwright upped their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Citigroup began coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $52.00 price target on the stock. Stephens restated an "overweight" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Finally, BTIG Research began coverage on Kymera Therapeutics in a report on Tuesday, December 10th. They set a "buy" rating and a $60.00 target price on the stock. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Kymera Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $56.36.

Remove Ads

Kymera Therapeutics Price Performance

Shares of KYMR traded up $2.90 during mid-day trading on Wednesday, hitting $23.95. 1,790,274 shares of the company's stock were exchanged, compared to its average volume of 543,247. The company has a 50-day simple moving average of $32.23 and a 200 day simple moving average of $40.16. The company has a market cap of $1.56 billion, a PE ratio of -10.24 and a beta of 2.22. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. On average, analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Activity at Kymera Therapeutics

In other news, COO Jeremy G. Chadwick sold 1,383 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the transaction, the chief operating officer now owns 67,800 shares of the company's stock, valued at $2,064,510. This trade represents a 2.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Bruce N. Jacobs sold 7,035 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,659 shares of company stock valued at $324,567. 15.82% of the stock is owned by insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.